Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 3Myeloid 2Plasma cell 1Classical hematology 1

Conditions

Multiple Myeloma 9Waldenstrom Macroglobulinemia 2Neoplasms, Plasma Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multi-centric Castleman's Disease 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hematologic Neoplasms 1HIV Infections 1Burkitt Lymphoma 1

Interventions

fludarabine phosphate 19fludarabine 18Cyclophosphamide 16Tacrolimus 12Whole-Body Irradiation 11Melphalan 11Mycophenolic Acid 10Bortezomib 9Busulfan 8trametinib 7Dexamethasone 7thymoglobulin 6Stem Cell Transplantation 6Lenalidomide 6Cyclosporine 6Sirolimus 5Nivolumab 5Methotrexate 5dabrafenib 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Granulocyte Colony-Stimulating Factor 4Antilymphocyte Serum 4Alemtuzumab 4daratumumab 3aldesleukin 3Thiotepa 3Specimen Handling 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × ibrutinib × Plasma cell × Clear all
NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Sumitomo Pharma America, Inc.

Phase 1 Completed
15 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡